CA3056396A1 - Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates - Google Patents

Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates Download PDF

Info

Publication number
CA3056396A1
CA3056396A1 CA3056396A CA3056396A CA3056396A1 CA 3056396 A1 CA3056396 A1 CA 3056396A1 CA 3056396 A CA3056396 A CA 3056396A CA 3056396 A CA3056396 A CA 3056396A CA 3056396 A1 CA3056396 A1 CA 3056396A1
Authority
CA
Canada
Prior art keywords
composition
cells
cancer
factor vii
icon3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3056396A
Other languages
English (en)
French (fr)
Inventor
Zhiwei Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CA3056396A1 publication Critical patent/CA3056396A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3056396A 2017-03-14 2018-03-14 Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates Pending CA3056396A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762471045P 2017-03-14 2017-03-14
US62/471,045 2017-03-14
US201762576278P 2017-10-24 2017-10-24
US62/576,278 2017-10-24
US201862623269P 2018-01-29 2018-01-29
US62/623,269 2018-01-29
PCT/US2018/022443 WO2018170134A1 (en) 2017-03-14 2018-03-14 Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates

Publications (1)

Publication Number Publication Date
CA3056396A1 true CA3056396A1 (en) 2018-09-20

Family

ID=63523847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3056396A Pending CA3056396A1 (en) 2017-03-14 2018-03-14 Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates

Country Status (8)

Country Link
US (2) US11872194B2 (https=)
EP (1) EP3595707A4 (https=)
JP (1) JP7155144B2 (https=)
CN (1) CN110520152A (https=)
AU (1) AU2018235945A1 (https=)
CA (1) CA3056396A1 (https=)
MA (1) MA47786A (https=)
WO (1) WO2018170134A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING
WO2022106648A1 (en) 2020-11-20 2022-05-27 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5166197A (en) 1990-07-17 1992-11-24 Kenney Malcolm E Phthalocyanine photosensitizers for photodynamic therapy
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
DK1198479T3 (da) 1999-07-01 2008-10-13 Univ Yale Neovaskulamålrettet immunkonjugat
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
BR112018001148A2 (pt) * 2015-08-06 2018-09-11 Glycotope Gmbh heterômeros compreendendo proteínas de fusão com domínios de anticorpos
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION

Also Published As

Publication number Publication date
AU2018235945A1 (en) 2019-10-17
JP2020511140A (ja) 2020-04-16
US20200085922A1 (en) 2020-03-19
JP7155144B2 (ja) 2022-10-18
MA47786A (fr) 2020-01-22
EP3595707A1 (en) 2020-01-22
US11872194B2 (en) 2024-01-16
WO2018170134A1 (en) 2018-09-20
CN110520152A (zh) 2019-11-29
EP3595707A4 (en) 2021-01-13
US20240123042A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP6803315B2 (ja) エンドグリンポリペプチドおよびその使用
CN102281890B (zh) Sparc结合肽及其应用
US9498509B2 (en) TIMP3 as VEGF inhibitor
KR101309948B1 (ko) 혈관 신생 억제 화합물
US20240123042A1 (en) Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
JP6744391B2 (ja) Ｔｏｓｏ活性を調節するための方法および組成物
KR102461210B1 (ko) Uti 융합 단백질
US20060199248A1 (en) Q3 SPARC deletion mutant and uses thereof
JP2021006581A (ja) 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用
JP2015506961A (ja) Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
US20190153119A1 (en) Compositions and methods for treating disorders associated with neovascularization
US8431396B2 (en) Anti-angiogenic peptides
JP2023134469A (ja) 組織因子標的化ｃａｒ－ｎｋ及びｃａｒ－ｔ細胞療法
JP5822407B2 (ja) 軟骨・骨破壊抑制剤
JP2014091687A (ja) 軟骨又は骨の破壊の診断薬

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921